Kittysak Caucharan
The FDA stated Thursday it has beneficial that COVID-19 vaccine producers use the KP.2 pressure to supply up to date vaccines for the 2024-2025 season.
An advisory panel to the company voted unanimously on June 5 to suggest the JN.1 pedigree Vaccine for this season’s SARS-CoV-2 virus. The committee additionally mentioned the proposed use of the JN.1 pressure as a vaccine.
Based mostly on continued monitoring of circulating strains, the FDA now recommends using the KP.2 pressure (a so-called FLiRT variant) in vaccines this season when possible.
Each KP.2 and JN.1 strains are descendants of the JN.1 lineage.
The FDA stated the change shouldn’t delay the supply of a U.S. vaccine this yr.
COVID-19 vaccine producers focusing on the U.S. market embrace Pfizer (NYSE:PFE)/BioNTech (NASDAQ: BNTX), fashionable (NASDAQ: MRNA) and Novavax (NASDAQ: NVAX).
